All In Biotech

Drug Trial Radar · NCT03167307

The Omega-3 Fatty Acid Paediatric Depression Trial

OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study

Last checked: Nov 20, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 257 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

257

Actual

Start

Apr 28, 2017

Primary completion

Mar 24, 2022

Study completion Mar 24, 2022

Sponsor

Lead sponsor
Gregor BergerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Swiss National Science Foundation
First posted
May 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 8 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the therapeutic efficacy and safety of omega-3 fatty acids rich in eicosapentaenoic acid / docosahexaenoic acid in pediatric depression in a nine months double-blind multi-centre study in 220 children and adolescents between 8 and 17 years of age. Inflammatory and bioactive lipid markers as predictors of response are evaluated. The relationship between omega-3 fatty acids with psychopathology, illness course and cognitive parameters will be further investigated.

Conditions

  • Depression

Interventions

  • Omega 3 fatty acidDrug

    Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines

  • Placebo oilDrug

    medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptomatic improvementTime frame: 9 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University Psychiatric Services

    Basel, Switzerland

  • Stiftung Kinder- und Jugendpsychiatrische Dienste St.Gallen

    Sankt Gallen, Switzerland

  • Psychiatric Services Baselland

    Liestal, Basel-Landschaft, Switzerland

  • Psychiatric University Clinics, Department of Child and Adolescent Psychiatry

    Zurich, Canton of Zurich, Switzerland

  • Klinik Sonnenhof

    Ganterschwil, St.Gallen, Switzerland

  • Clienia Littenheid

    Littenheid, Thurgau, Switzerland

  • Spital Thurgau Kinder- und Jugendpsychiatrischer Dienst

    Weinfelden, Thurgau, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.